CytoReason vs FORE Biotherapeutics
CytoReason vs FORE Biotherapeutics, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and FORE Biotherapeutics on 56/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 56/100
- domain rating: 40/100 against 33/100
- headcount: 116 against 56
- headcount growth: +13.7% against +8.2%
- LinkedIn following: 12,830 against 4,584
FORE Biotherapeutics
- agent readiness: 37/100 against 21/100
- funding raised: $232M against $128M
At a glance
| Measure | CytoReason | FORE Biotherapeutics |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Precision oncology company developing cancer therapies guided by proprietary functional genomics. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Drug Development, Genomics, Next Generation Sequencing |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2011 |
| Headquarters | Tel Aviv, Israel | Philadelphia, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | FORE Biotherapeutics |
|---|---|---|
| Employees | 116 | 56 |
| Headcount growthLast 12 months | +13.7% | +8.2% |
| Total funding | $128M | $232M |
| Latest round | Series B | Series D-2 Extension |
| Valuation | Not published | $75.0M |
| LinkedIn followers | 12,830 | 4,584 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | FORE Biotherapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 56/100 |
| Traction | 60/100 | 58/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 30/100 | 38/100 |
| Quality | 78/100 | 55/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (37/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 33/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | FORE Biotherapeutics |
|---|---|---|
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Segment | Not detected |
CytoReason vs FORE Biotherapeutics: common questions
Which is better, CytoReason or FORE Biotherapeutics?
On our 0-100 score CytoReason rates higher (68/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CytoReason and FORE Biotherapeutics compare on the numbers?
CytoReason leads on our overall score (68/100 against 56/100), domain rating (40/100 against 33/100), headcount (116 against 56), headcount growth (+13.7% against +8.2%), LinkedIn following (12,830 against 4,584). FORE Biotherapeutics leads on agent readiness (37/100 against 21/100), funding raised ($232M against $128M).
Read the full CytoReason review and pricing or the FORE Biotherapeutics review and pricing. You can also browse other CytoReason alternatives we track.